May 28, 2025
mayank
HDFC Pharma And Healthcare Fund details, NAV, Portfolio, Returns, Peer Comparison, Fund Managers & Guidance by sahifund.com
NAV Growth: Rs 16.5370
NAV IDCW: Rs 16.5370
Suitable For Which Investors?
This is a fund that invests mainly in shares of pharmaceutical and healthcare companies.
We believe that investors should avoid funds that have a narrowly defined investment mandate such as this one. Instead, they should invest in flexi-cap funds which provide complete freedom to the fund management team to invest in companies from which it expects maximum gains.
But if you do invest, you must do so only through the SIP route.
Fund’s Investment Strategy:
The scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related securities of Pharma and healthcare companies.
Fund Manager:
1) Nikhil Mathur
Education: Mr. Mathur has done B.Tech and PGDM in Finance
Experience: Prior to joining HDFC Mutual Fund, he has worked with Ambit Capital, Goldman Sachs, Deloitte India and EY
Investment Details
| Min. Investment (Rs) | 100 |
| Min. Addl Investment (Rs) | 100 |
| Min. SIP Investment (Rs) | 100 |
| Min. Withdrawal (Rs) | — |
| Min. No of Cheques | 6 |
| Min. Balance (Rs) | — |
| Lock-in Period | NA |
| Exit Load | 1% for redemption within 30 days |
Basic Details of HDFC Pharma And Healthcare Fund
| Fund House | HDFC Mutual Fund |
| Launch Date | 04-Oct-23 |
| Return Since Launch | 35.73% |
| Benchmark | BSE Healthcare TRI |
| Riskometer | Very High |
| Type | Open-ended |
| Assets | Rs 1,666 Cr |
| (As on 30-Apr-2025) | |
| Expense | 0.83% |
| (As on 30-Apr-2025) | |
| Risk Grade | — |
| Return Grade | — |
| Turnover | 36.47% |
Trailing Returns (%) of HDFC Pharma And Healthcare Fund
| Fund name | YTD | 1D | 1M | 3M | 6M | 1Y | 3Y | 5Y | 7Y | 10Y |
| HDFC Pharma And Healthcare Dir | -4.33 | -0.23 | 1.55 | 9.26 | 0.87 | 29.43 | — | — | — | — |
| BSE Healthcare TRI | -5.60 | 0.01 | 1.87 | 9.23 | -0.62 | 20.98 | — | — | — | — |
| Equity: Sectoral-Pharma | -5.70 | -0.04 | 1.82 | 8.44 | -1.30 | 19.34 | — | — | — | — |
| Rank within category | 5 | 16 | 11 | 7 | 2 | 2 | — | — | — | — |
| Number of funds in category | 21 | 19 | 21 | 21 | 19 | 17 | 11 | 9 | 4 | 3 |
Peer Comparison of HDFC Pharma And Healthcare Fund
| Rating | 1 Year Returns | 3 Year Returns | 5 Year Returns | Expense Ratio (%) | Net Assets (Rs Cr) | Return Since Launch (%) | Exit Load (Days) | Fund Age | Turnover (%) | |
| HDFC Pharma And Healthcare Dir | Unrated | 29.43 | — | — | 0.83 | 1,666 | 35.73 | 1.00 (30) | 1Y 7M | 36.47 |
| ICICI Pru Pharma Healthcare and Diagnostics Dir | 4 star | 25.17 | 29.00 | 27.14 | 1.07 | 5,295 | 23.00 | 1.00 (15) | 6Y 10M | 81.00 |
| SBI Healthcare Opportunities Dir | 5 star | 23.13 | 27.99 | 25.97 | 0.90 | 3,671 | 18.18 | 0.50 (15) | 12Y 4M | 24.00 |
| DSP Healthcare Dir | 4 star | 16.24 | 24.82 | 26.02 | 0.62 | 2,912 | 24.52 | 0.50 (30) | 6Y 5M | 22.00 |
| Tata India Pharma & Healthcare Dir | 4 star | 17.31 | 24.83 | 23.90 | 0.67 | 1,223 | 13.93 | 0.25 (30) | 9Y 5M | 13.77 |
Portfolio Analysis of HDFC Pharma And Healthcare Fund
| No. of Stocks | 31 |
| Top 10 Stocks | 58.00% |
| Top 5 Stocks | 39.83% |
| Top 3 Sectors | 98.41% |
| Portfolio P/B Ratio | 5.54 |
| Portfolio P/E Ratio | 31.81 |
Portfolio Breakup
| Fund | Category | |
| Average Mkt Cap (Rs Cr) | 57,528 | 80,210 |
| Giant (%) | 22.43 | 24.32 |
| Large (%) | 29.23 | 36.03 |
| Mid (%) | 36.81 | 32.26 |
| Small (%) | 11.53 | 9.54 |
| Tiny (%) | — | 0.03 |
Chanakya’s Mutual Fund Guidance For HDFC Pharma And Healthcare Fund
WILL Post Soon
Disclaimer: Mutual fund investments are subject to market risks. Read all scheme related documents carefully
Apply Online: https://investor-web.hdfcfund.com/ (This like open Microsoft Edge & Internet Explorer)
>> Post your MF questions @ sahifund.com/ask-me/
>> NFO Guidance:
https://sahifund.com/category/nfos/
Quicklinks